Brilliant! Last line from Jackie is key. DEP technology has...

Brilliant! Last line from Jackie is key. DEP technology has massive potential scalability.

Dr Fairley commented: “The phase 1 results are particularly pleasing given that they are the first human trial results utilising Starpharma’s proprietary DEP® drug delivery platform. The results demonstrate the benefits of our DEP® technology in delivering drugs in a way that modifies conventional pharmacokinetics to reduce certain life-threatening and dose-limiting toxicities. We’re excited to have validated our preclinical findings with DEP® docetaxel and anticipate that the momentum around our internal and partnered DEP® programs will continue to build as we advance this and our other DEP® candidates. These impressive clinical results are not only relevant for DEP® docetaxel itself but also provide important clinical validation that adds further value to Starpharma’s proprietary DEP® platform more broadly.”